ClinicalTrials.gg
CompletedNCT07413133Updated Jul 20, 2026

A Study to Assess How the Body Absorbs ABBV-8736 Subcutaneous Injections Relative to Intravenous Injections in Adult Healthy Volunteers

A Phase 1 interventional study of ABBV-8736 and ABBV-8736 in Healthy Volunteer, sponsored by AbbVie. Completed at 2 sites in United States. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-20.

Sponsored by AbbVie · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Study summary

The purpose of this study is to assess the pharmacokinetics (PK), bioavailability, immunogenicity, safety, and tolerability of ABBV-8736 following subcutaneous (SC) administration relative to intravenous (IV) administration.

02

Conditions studied

  • Healthy Volunteer

Keywords

  • Healthy Volunteer
  • ABBV-8736
03

In context

Lead sponsor

AbbVie is the lead sponsor of 977 studies on the registry; 136 are open to participants now.

Of its 359 completed or terminated interventional studies of FDA-regulated products, 215 (60%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • (BMI) is >= 18.0 to \<= 32.0 kg/m2 after rounding to the tenths decimal. BMI is calculated as weight in kg divided by the square of height measured in meters.
  • Body weight >= 35 kg.
  • A condition of general good health, based upon the results of a medical history, physical examination, vital signs, laboratory profile and a 12-lead (ECG).

Exclusion criteria

Exclusion Criteria:

  • Participant requires any over-the-counter and/or prescription medication, vitamins, and/or herbal supplements, on a regular basis.
  • Participant uses any medications, vitamins and/or herbal supplements within the 14-day period prior to study treatment administration.
  • Participant has received any treatment by injection within 30 days or within a period defined by 5 half-lives, whichever is longer, prior to study treatment administration.
  • Participant has prior exposure to a Triggering Receptor Expressed on Myeloid Cells 1 (TREM1) agent.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
40 participants (actual)

Study arms

  • Experimental
    Arm 1: Intravenous (IV) ABBV-8736

    Participants will receive IV ABBV-8736 on Day 1.

    Drug: ABBV-8736

  • Experimental
    Arm 2: Subcutaneous (SC) ABBV-8736

    Participants will receive SC ABBV-8736 on Day 1.

    Drug: ABBV-8736

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Participants with Adverse Events (AEs)

    An AE is defined as any untoward medical occurrence in a patient or clinical investigation in which a participant is administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment.

    Time frame: Up to At Least 3 Months

  2. Maximum Observed Serum Concentration (Cmax) of ABBV-8736

    Cmax of ABBV-8736.

    Time frame: Up to At Least 3 Months

  3. Time to Maximum Observed Serum Concentration (Tmax) of ABBV-8736

    Tmax of ABBV-8736.

    Time frame: Up to At Least 3 Months

  4. Area Under the Plasma Concentration-Time Curve (AUC) From Time 0 to the Time Last (AUClast) of ABBV-8736

    AUClast of ABBV-8736.

    Time frame: Up to At Least 3 Months

  5. AUC From Time 0 to the Time Infinity (AUCinf) of ABBV-8736

    AUCinf of ABBV-8736.

    Time frame: Up to At Least 3 Months

  6. Terminal Phase Elimination Rate Constant (β) of ABBV-8736

    β of ABBV-8736.

    Time frame: Up to At Least 3 Months

  7. Terminal Elimination Half-Life (t1/2) of ABBV-8736

    t1/2 of ABBV-8736.

    Time frame: Up to At Least 3 Months

  8. Apparent Clearance of the Analyte in Serum (CL) of ABBV-8736

    CL of ABBV-8736.

    Time frame: Up to At Least 3 Months

07

Study locations

2 sites
  • CenExel ACT- Anaheim Clinical Trials /ID# 280481
    Anaheim, California 92801, United States
  • Acpru /Id# 280382
    Grayslake, Illinois 60030, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2026 to primary completion in Jun 2026, 4 months.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 10, 2026
First posted
Feb 17, 2026
StartActual
Feb 11, 2026
Primary completionActual
Jun 19, 2026
CompletionActual
Jun 19, 2026
Last update
Jul 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07413133
Lead sponsor
AbbVie
Responsible party
Sponsor
First posted
Feb 17, 2026
Start date
Feb 11, 2026
Primary completion
Jun 19, 2026
Completion
Jun 19, 2026
Last update
Jul 20, 2026

Study contacts

ABBVIE INC.
study director · AbbVie

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: ABBV-8736

Start the discussion